IRAK4 and rhabdomyolysis: Moreover, no signals for rhabdomyolysis were observed, which is in contrast to experiences with emavusertib (CA-4948) (a combined IRAK4/FLT3-inhibitor), for which a partial clinical (FDA)-hold was set in place due to a case of lethal rhabdomyolysis in an oncologic clinical study (treatment in7 combination with azacitidine or venetoclax).